[Varicella Zoster Immune Globulin (Human)] for Injection
VARIZIG [Varicella Zoster Immune Globulin (Human)] is a solvent/detergent-treated sterile lyophilized preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). VZV is the causative agent of chickenpox. VARIZIG is prepared from plasma donated by healthy, screened donors with high titers of antibodies to VZV, which is purified by an anion-exchange column chromatography manufacturing method. This donor selection process includes donors with high anti-VZV titers due to recent natural infection by VZV, or due to recurrent zoster infection (shingles).
VARIZIG is supplied as a kit containing a single use vial of VARIZIG (lyophilized powder for solution for intramuscular injection with a potency of 125 IU) and a vial of 8.5 milliliters Sterile Diluent, which is used for reconstitution of the product prior to administration. VARIZIG is intended for single use and should be administered intramuscularly [see DOSAGE AND ADMINISTRATION].
The product potency is expressed in IU by comparison to the World Health Organization (WHO) international reference preparation for anti-VZV immune globulin. Each vial contains 125 IU of anti-VZV. The lyophilized VARIZIG is formulated as 0.04 M sodium chloride, 0.1 M glycine and 0.01% polysorbate 80. The accompanying Sterile Diluent contains 0.8% sodium chloride and 10 mM sodium phosphate. The reconstituted VARIZIG has a pH of 7 and contains no preservative.
VARIZIG has not been tested for the presence of anti-Protein S antibodies that have been reported to arise transiently after VZV infection (4); however, it is assumed that the requirement that donors be healthy will alleviate this concern.
The source plasma used in the manufacture of this product was tested by FDA licensed nucleic acid testing (NAT) for human immunodeficiency virus-1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) and found to be negative. Plasma also was tested by inprocess NAT for hepatitis A virus (HAV) and parvovirus B19 (B19) via minipool testing; the limit for B19 in the manufacturing pool is set not to exceed 104 IU of B19 DNA per milliliter.
The manufacturing process contains two steps implemented specifically for virus clearance. The solvent/detergent step (using tri-n-butyl phosphate and Triton X-100) is effective in the inactivation of enveloped viruses, such as HBV, HCV and HIV-1. Virus filtration, using a Planova 20N virus filter, is effective for the removal of viruses based on their size, including some non-enveloped viruses. These two viral clearance steps are designed to increase product safety by reducing the risk of transmission of enveloped and non-enveloped viruses. In addition to these two specific steps, the process step of anion-exchange chromatography was identified as contributing to the overall viral clearance capacity for small non-enveloped viruses.
The inactivation and reduction of known enveloped and non-enveloped model viruses were validated in laboratory studies as summarized in Table 3. The viruses employed for spiking studies were selected to represent those viruses that are potential contaminants in the product, and to represent a wide range of physiochemical properties in order to challenge the manufacturing process's ability for viral clearance in general.
Table 3 : Virus Reduction Values (Log10)
Obtained through Validation Studies
|Anion Exchange Chromatography (partitioning)||Not evaluated||2.3||n.e.||3.4||n.e.|
|20N Filtration (size exclusion)||≥ 4.7||≥ 3.5||≥ 5.6*||n.e.||4.8||n.e.||4.1|
|Solvent/Detergent (inactivation)||≥ 4.7||≥ 7.3||≥ 5.5||Not evaluated|
|Total Reduction (log10)||≥ 9.4||≥ 10.8||≥ 11.1||2.3||4.8||3.4||4.1|
|*The PRV was retained by the 0.1 |am pre-filter during
the virus validation. Since manufacturing employs a 0.1 ľam pre-filter before
the 20N filter, the claim of ≥ 5.6 reduction is considered applicable.
HIV-1: human immunodeficiency virus-1; relevant virus for human immunodeficiency virus-1 and model for HIV-2
BVDV: bovine viral diarrhea virus; model virus for hepatitis C virus (HCV) and West Nile virus (WNV)
PRV: pseudorabies virus; model for large enveloped DNA viruses, including herpes
HAV: human hepatitis A virus; relevant virus for HAV and model for small non-enveloped viruses in general
EMC: encephalomyocarditis virus; model for HAV and for small non-enveloped viruses in general
MMV: murine minute virus; model for human parvovirus B19 and for small non-enveloped viruses in general
n.e.: not evaluated
Last reviewed on RxList: 2/19/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional VariZIG Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.